![Sunil Chauhan](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
David Tierney | M | 60 |
Aramis Biosciences, Inc.
![]() Aramis Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Aramis Biosciences is a clinical-stage immuno-ophthalmology biopharmaceutical company based in Medfield, MA. Aramis Biosciences is committed to developing disease-modifying therapy for ocular surface disease, starting with dry eye disease. The company's lead product candidate, A197, is a novel, first-in-class, topical immunomodulatory agent currently in a phase II clinical proof of concept for the treatment of dry eye disease. The company was founded in 2018 by Sunil Chauhan, Reza Dana, and the CEO is David S. Tierney. Aramis Biosciences was founded by leading experts in the fields of corneal disorders, ocular inflammation, and immunology from the Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, with support from Safar Partners, Dompé Farmaceutici S.p.A., and a leader in ophthalmic pharmaceuticals. | - |
Nader Motamedy | M | - |
Aramis Biosciences, Inc.
![]() Aramis Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Aramis Biosciences is a clinical-stage immuno-ophthalmology biopharmaceutical company based in Medfield, MA. Aramis Biosciences is committed to developing disease-modifying therapy for ocular surface disease, starting with dry eye disease. The company's lead product candidate, A197, is a novel, first-in-class, topical immunomodulatory agent currently in a phase II clinical proof of concept for the treatment of dry eye disease. The company was founded in 2018 by Sunil Chauhan, Reza Dana, and the CEO is David S. Tierney. Aramis Biosciences was founded by leading experts in the fields of corneal disorders, ocular inflammation, and immunology from the Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, with support from Safar Partners, Dompé Farmaceutici S.p.A., and a leader in ophthalmic pharmaceuticals. | - |
Michael H. Goldstein | M | 57 |
Aramis Biosciences, Inc.
![]() Aramis Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Aramis Biosciences is a clinical-stage immuno-ophthalmology biopharmaceutical company based in Medfield, MA. Aramis Biosciences is committed to developing disease-modifying therapy for ocular surface disease, starting with dry eye disease. The company's lead product candidate, A197, is a novel, first-in-class, topical immunomodulatory agent currently in a phase II clinical proof of concept for the treatment of dry eye disease. The company was founded in 2018 by Sunil Chauhan, Reza Dana, and the CEO is David S. Tierney. Aramis Biosciences was founded by leading experts in the fields of corneal disorders, ocular inflammation, and immunology from the Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, with support from Safar Partners, Dompé Farmaceutici S.p.A., and a leader in ophthalmic pharmaceuticals. | - |
Tsuyoshi Chiwata | M | - |
Aramis Biosciences, Inc.
![]() Aramis Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Aramis Biosciences is a clinical-stage immuno-ophthalmology biopharmaceutical company based in Medfield, MA. Aramis Biosciences is committed to developing disease-modifying therapy for ocular surface disease, starting with dry eye disease. The company's lead product candidate, A197, is a novel, first-in-class, topical immunomodulatory agent currently in a phase II clinical proof of concept for the treatment of dry eye disease. The company was founded in 2018 by Sunil Chauhan, Reza Dana, and the CEO is David S. Tierney. Aramis Biosciences was founded by leading experts in the fields of corneal disorders, ocular inflammation, and immunology from the Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, with support from Safar Partners, Dompé Farmaceutici S.p.A., and a leader in ophthalmic pharmaceuticals. | - |
Gráfico relacional
Relaciones con varias empresas
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 4 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Sunil Chauhan
- Red Personal